FDA approval of ISEMBYLD opens the SMA commercialization pathway, with meaningful valuation upside and execution risk

Key Facts

• Scholar Rock was awarded a Rare Pediatric Disease Priority Review Voucher in connection with the ISEMBYLD approval; the voucher may be used to obtain priority review for a future marketing application.
• The company has launched Scholar Rock Supports for prescribed patients, including assistance with insurance coverage, eligible financial assistance, treatment education, site-of-care options, and infusion logistics; ISEMBYLD is expected to be available to ship in the coming days.
• Scholar Rock said it is working with commercial and government payers to establish reliable, broad access to ISEMBYLD for appropriate patients.

Source

View the source SEC filing